Charlie Kirk Threat Fallout: Free Speech Gets Fired, CDC Flips MMRV Script
In the latest episode of America’s ongoing ‘Free Speech Fiasco,’ folks commenting on Charlie Kirk’s assassination fantasies are dropping jobs faster than a COVID variant spreads. Meanwhile, the CDC vaccine panel, probably tired of the same old vaccine drama, has rolled back its MMRV vaccine guidance—a move that even your conspiracy theorist uncle might find unexpected. It’s politics and public health colliding like a badly scripted reality TV show: one side losing careers over words, the other rewriting childhood vaccine rules, because apparently, even public health committees enjoy a plot twist in 2024.
Share the Story
(1 of 3)When free speech causes more unemployment than a robot uprising and the CDC is busy playing whack-a-mole with vaccine rules, you know 2024 is shaping up to be a masterclass in chaos theory.
Charlie Kirk’s assassination chat turns into a job purge faster than you can say 'cancel culture.' Meanwhile, the CDC quietly edits vaccine rules—because why not add a pinch of chaos to your immunity?
Free speech in 2024 is basically a ‘handle with care’ label: one wrong word and you’re out. And while people lose jobs over tweets, the CDC’s just out here flipping MMRV guidance like a chef with a rebellious recipe.
Source: Feeds | Published: 9/19/2025 | Author: Brittney Melton
More Articles in US News
DeSantis Begs Trump For Job; Settles On AG, War, or Supreme Court Like A Drive-Thru Menu
Trump Nominee Promises Fed Independence While Holding $100M in Mystery Investments
Framework Laptop 13 Pro Promises No More 'Gorilla Arm' Pain, Still No Battery Bliss
Visitors Shocked To Learn National Parks Aren't WiFi Cafes, Bears Actually Mean Business
Uber Debates Whether $5,000 or $8.5 Million Is 'Tiny Fraction' of Reality
FBI Director Sues Magazine for Reporting He Might Drink a Little Too Much
United Flight Diverted Over Mysterious Beeping, Because That Sounds Totally Normal
Texas Cities Win Again, Because Who Needs Affordable Homes Anywhere Else?
